OMLYCLO

NDC product · U.S. Food and Drug Administration (openFDA) · United States

  • Product NDC 72606-054
  • Package NDC 72606-054-01
  • Package NDC 72606-054-02
  • Application number BLA761399
  • SPL ID 0cfb7a85-6b8a-4530-aa3f-5a6aa7422d73
  • SPL set ID dbd8709f-1636-45d9-ba94-5a3bc5f22f84
  • UNII 2P471X1Z11
  • RxCUI 2726001
  • RxCUI 2726008
  • RxCUI 2726010
  • RxCUI 2726011
  • RxCUI 2735283
  • RxCUI 2751593

What the source publishes

Labeler
CELLTRION USA, Inc.
Active ingredients
omalizumab-igec
Form
INJECTION
Routes
SUBCUTANEOUS
Administrative status
present-in-source-snapshot
Marketing status
BLA
Product type
HUMAN PRESCRIPTION DRUG
Prescription
Prescription or restricted

Names this record is found by

Complete source data
us:fda:ndc:72606-054_0cfb7a85-6b8a-4530-aa3f-5a6aa7422d73
{
  "name": "OMLYCLO",
  "splId": "0cfb7a85-6b8a-4530-aa3f-5a6aa7422d73",
  "labels": [
    {
      "setId": "dbd8709f-1636-45d9-ba94-5a3bc5f22f84",
      "labelUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbd8709f-1636-45d9-ba94-5a3bc5f22f84",
      "labelPdfUrl": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=dbd8709f-1636-45d9-ba94-5a3bc5f22f84"
    }
  ],
  "routes": [
    "SUBCUTANEOUS"
  ],
  "labeler": "CELLTRION USA, Inc.",
  "finished": true,
  "packaging": [
    {
      "sample": false,
      "description": "1 SYRINGE, GLASS in 1 CARTON (72606-054-01)  / 2 mL in 1 SYRINGE, GLASS",
      "package_ndc": "72606-054-01",
      "identifierStatus": "well-formed",
      "marketing_start_date": "20261005"
    },
    {
      "sample": false,
      "description": "2 SYRINGE, GLASS in 1 CARTON (72606-054-02)  / 2 mL in 1 SYRINGE, GLASS",
      "package_ndc": "72606-054-02",
      "identifierStatus": "well-formed",
      "marketing_start_date": "20261005"
    }
  ],
  "productId": "72606-054_0cfb7a85-6b8a-4530-aa3f-5a6aa7422d73",
  "useDomain": "unknown",
  "dosageForm": "INJECTION",
  "productNdc": "72606-054",
  "deaSchedule": null,
  "genericName": "omalizumab-igec",
  "productType": "HUMAN PRESCRIPTION DRUG",
  "listingStatus": "present-in-source-snapshot",
  "targetSpecies": [],
  "approvalStatus": "not-established-by-ndc-listing",
  "labelAssociation": "openFDA-harmonized-set-ids; not a product-level approval match",
  "marketingEndDate": null,
  "activeIngredients": [
    {
      "name": "OMALIZUMAB",
      "strength": "300 mg/2mL"
    }
  ],
  "applicationNumber": "BLA761399",
  "marketingCategory": "BLA",
  "stateRestrictions": {
    "status": "not-collected",
    "observations": []
  },
  "useDomainEvidence": {
    "basis": "unreviewed",
    "field": null,
    "value": null,
    "version": 1,
    "sourceId": "us.fda.ndc"
  },
  "marketingStartDate": "20261005",
  "targetSpeciesStatus": "not-reported",
  "prescriptionCategory": "prescription-or-restricted",
  "harmonizedIdentifiers": {
    "nui": [
      "N0000175794",
      "N0000175793",
      "N0000175792"
    ],
    "unii": [
      "2P471X1Z11"
    ],
    "rxcui": [
      "2726001",
      "2726008",
      "2726010",
      "2726011",
      "2735283",
      "2751593"
    ],
    "spl_set_id": [
      "dbd8709f-1636-45d9-ba94-5a3bc5f22f84"
    ],
    "pharm_class_pe": [
      "Decreased IgE Activity [PE]"
    ],
    "pharm_class_epc": [
      "Anti-IgE [EPC]"
    ],
    "pharm_class_moa": [
      "IgE-directed Antibody Interactions [MoA]"
    ],
    "manufacturer_name": [
      "CELLTRION USA, Inc."
    ],
    "is_original_packager": [
      true
    ]
  },
  "listingExpirationDate": "20271231"
}

Read this record from your own software

The same record, with every field and its provenance, is one request away. An API key is free and works immediately.

GET /v1/drugs/record
curl -G "https://api.medifontis.com/v1/drugs/record" \
  -H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
  --data-urlencode "country=us" \
  --data-urlencode "sourceId=us.fda.ndc" \
  --data-urlencode "id=us:fda:ndc:72606-054_0cfb7a85-6b8a-4530-aa3f-5a6aa7422d73"